Skip to main content

Table 1 Active Recruiting Current Clinical Trials with CSF-1R Inhibitors in Various Malignancies

From: Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

NCI Identifier Study Description Tumor Type Drug Combination with CSF-1R inhibitor* Phase
NCT02777710 Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Advanced Cancers, Colorectal, Pancreatic Cancer Durvalumab
Pexidartinib(PLX-3397)*
I
NCT02401815 PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors Gastrointestinal Stromal Tumors PLX-3397*
PLX9486
Sunitinib
I/II
NCT02071940 PLX3397 KIT in Acral and mucosal Melanoma Melanoma PLX-3397* II
NCT02584647 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Sarcoma, Malignant Peripheral Nerve Sheath Tumors Sirolimus
PLX-3397*
I/II
NCT03069469 Study of DCC-3014 in Patients With Advanced Malignancies Advanced Malignant DCC-3014* I
NCT02880371 A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Advanced Solid Tumors, Platinum Resistant ovarian cancer, pancreatic ductal adenocarcinoma ARRY-382*
Pembrolizumab
I/II
NCT02829723 Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Advanced Solid Tumors BLZ945*
PDR001
I/II
  1. *There are also clinical trials evaluating monoclonal Antibodies Targeting CSF-1R, including NCT02718911, NCT03238027, NCT02471716, NCT03101254, NCT03336216, NCT03431948, and NCT03335540, which are assessing LY3022855, SNDX-6352, FPA008 (Cabiralizumab), LY3022855, FPA008, FPA008 and FPA008, respectively